RT Journal Article
SR Electronic
T1 Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 859
OP 864
DO 10.21873/invivo.12774
VO 36
IS 2
A1 SHINYA YAMAMOTO
A1 TAKASHI CHISHIMA
A1 YUKAKO SHIBATA
A1 SHIORI INOUE
A1 FUMI HARADA
A1 HIDEKI TAKEUCHI
A1 AKIMITSU YAMADA
A1 KAZUTAKA NARUI
A1 ITARU ENDO
YR 2022
UL http://iv.iiarjournals.org/content/36/2/859.abstract
AB Background/Aim: There are few models predicting breast cancer prognosis among patients receiving neoadjuvant chemotherapy (NAC) for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative (luminal) breast cancer. We examined whether biological features (BFs) of residual tumors are prognostic factors following NAC. Patients and Methods: We enrolled patients with remnant tumors following NAC for luminal breast cancer and evaluated clinical stage, pathological stage, BFs prior to NAC, and BFs following NAC as prognostic factors. BFs were divided into high and low risk using the previously reported YR-IHC4 model calculated according to ER, progesterone receptor (PgR), HER2, and the proliferation marker Ki-67. Results: A total of 57 patients were enrolled in the current study. We observed a statistically significant difference in relapse-free survival (RFS) between the BF risk categories via YR-IHC4 predictions following NAC (p=0.044). The 5-year RFS rates of the BF low- and high-risk groups following NAC were 84.2% and 52.5%, respectively. Conclusion: BFs of residual tumors following NAC may be important prognostic factors in luminal breast cancer.